Should You Buy Definium Therapeutics Inc (DFTX) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
17.480
1 Day change
5.88%
52 Week Range
--
Analysis Updated At
2026/01/25
Definium Therapeutics Inc (DFTX) does not present a strong buy opportunity for a beginner, long-term investor at this time. While there is a positive analyst rating and an increased price target, the company's financials show significant losses with no revenue growth. Additionally, there are no significant trading signals or recent congress trading data to support a buy decision. The lack of strong positive catalysts and the absence of clear technical trends further suggest holding off on investment for now.
Technical Analysis
No data available for trend analysis. The stock closed at $17.48 with a 2.53% increase during the regular market session and a 0.46% increase post-market. However, no clear technical trend can be identified.
Options Data
Positive Catalysts
2026/01/25 23:22:48
RBC Capital raised the price target to $36 from $20, citing increased expectations for the lead drug DT120's long-term sales opportunity. Positive sentiment from analysts following the Psychedelics Symposium.
Neutral/Negative Catalysts
2026/01/25 23:22:48
Hedge funds and insiders are neutral, indicating no significant trading activity. No recent congress trading data or strong trading signals available.
Financial Performance
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$67.27 million (up 391.56% YoY), and an EPS of -0.78 (up 333.33% YoY). Gross margin remained at 0%.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
RBC Capital maintains an Outperform rating and increased the price target to $36 from $20, citing optimism about the lead drug DT120's sales potential.
Wall Street analysts forecast DFTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DFTX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0
Wall Street analysts forecast DFTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DFTX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
0
Current: 16.510
Low
0
Averages
0
High
0
0
Current: 16.510
Low
0
Averages
0
High
0
RBC Capital
Outperform
upgrade
$20 -> $36
AI Analysis
2026-01-23
New
Reason
RBC Capital
Price Target
$20 -> $36
AI Analysis
2026-01-23
New
upgrade
Outperform
Reason
RBC Capital raised the firm's price target on Definium Therapeutics to $36 from $20 and keeps an Outperform rating on the shares. Following the firm's Psychedelics Symposium and discussions with the management, the firm has increased expectations for lead drug DT120's long-term sales opportunity, the analyst tells investors in a research note.
